Patents by Inventor Jimmy Cheng-Ho Lin
Jimmy Cheng-Ho Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210317532Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in gliblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: ApplicationFiled: November 6, 2020Publication date: October 14, 2021Inventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell Bigner, Chien-Tsun Kuan, Gregory J. Riggins
-
Patent number: 10894987Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: GrantFiled: November 16, 2016Date of Patent: January 19, 2021Assignees: The Johns Hopkins University, Duke UniversityInventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell D. Bigner, Chien-Tsun Kuan, Gregory J. Riggins
-
Patent number: 10837064Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in gliblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: GrantFiled: March 22, 2018Date of Patent: November 17, 2020Assignees: The Johns Hopkins University, Duke UniversityInventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell Bigner, Chien-Tsun Kuan, Gregory J. Riggins
-
Patent number: 10787712Abstract: Analysis of 13,023 genes in 11 breast and 11 colorectal cancers revealed that individual tumors accumulate an average of ˜90 mutant genes but that only a subset of these contribute to the neoplastic process. Using stringent criteria to delineate this subset, we identified 189 genes (average of 11 per tumor) that were mutated at significant frequency. The vast majority of these genes were not known to be genetically altered in tumors and are predicted to affect a wide range of cellular functions, including transcription, adhesion, and invasion. These data define the genetic landscape of two human cancer types, provide new targets for diagnostic and therapeutic intervention and monitoring.Type: GrantFiled: March 19, 2020Date of Patent: September 29, 2020Assignee: The Johns Hopkins UniversityInventors: Tobias Sjoblom, Sian Jones, D. Williams Parsons, Laura D. Wood, Jimmy Cheng-Ho Lin, Thomas Barber, Diana Mandelker, Bert Vogelstein, Kenneth W. Kinzler, Victor E. Velculescu
-
Publication number: 20200239970Abstract: Analysis of 13,023 genes in 11 breast and 11 colorectal cancers revealed that individual tumors accumulate an average of ˜90 mutant genes but that only a subset of these contribute to the neoplastic process. Using stringent criteria to delineate this subset, we identified 189 genes (average of 11 per tumor) that were mutated at significant frequency. The vast majority of these genes were not known to be genetically altered in tumors and are predicted to affect a wide range of cellular functions, including transcription, adhesion, and invasion. These data define the genetic landscape of two human cancer types, provide new targets for diagnostic and therapeutic intervention and monitoring.Type: ApplicationFiled: March 19, 2020Publication date: July 30, 2020Inventors: Tobias SJOBLOM, Sian JONES, D. Williams PARSONS, Laura D. WOOD, Jimmy Cheng-Ho LIN, Thomas BARBER, Diana MANDELKER, Bert VOGELSTEIN, Kenneth W. KINZLER, Victor E. VELCULESCU
-
Patent number: 10704108Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in gliblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: GrantFiled: September 17, 2018Date of Patent: July 7, 2020Assignees: The Johns Hopkins University, Duke UniversityInventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell Bigner, Chien-Tsun Kuan, Gregory J. Riggins
-
Publication number: 20200048719Abstract: Analysis of 13,023 genes in 11 breast and 11 colorectal cancers revealed that individual tumors accumulate an average of ˜90 mutant genes but that only a subset of these contribute to the neoplastic process. Using stringent criteria to delineate this subset, we identified 189 genes (average of 11 per tumor) that were mutated at significant frequency. The vast majority of these genes were not known to be genetically altered in tumors and are predicted to affect a wide range of cellular functions, including transcription, adhesion, and invasion. These data define the genetic landscape of two human cancer types, provide new targets for diagnostic and therapeutic intervention and monitoring.Type: ApplicationFiled: October 25, 2019Publication date: February 13, 2020Inventors: Tobias SJOBLOM, Sian JONES, D. Williams PARSONS, Laura D. WOOD, Jimmy Cheng-Ho LIN, Thomas BARBER, Diana MANDELKER, Bert VOGELSTEIN, Kenneth W. KINZLER, Victor E. VELCULESCU
-
Publication number: 20190106752Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in gliblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: ApplicationFiled: September 17, 2018Publication date: April 11, 2019Inventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell Bigner, Chien-Tsun Kuan, Gregory J. Riggins
-
Publication number: 20180282821Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in gliblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: ApplicationFiled: March 22, 2018Publication date: October 4, 2018Inventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell Bigner, Chien-Tsun Kuan, Gregory J. Riggins
-
Publication number: 20170362659Abstract: Analysis of 13,023 genes in 11 breast and 11 colorectal cancers revealed that individual tumors accumulate an average of ˜90 mutant genes but that only a subset of these contribute to the neoplastic process. Using stringent criteria to delineate this subset, we identified 189 genes (average of 11 per tumor) that were mutated at significant frequency. The vast majority of these genes were not known to be genetically altered in tumors and are predicted to affect a wide range of cellular functions, including transcription, adhesion, and invasion. These data define the genetic landscape of two human cancer types, provide new targets for diagnostic and therapeutic intervention and monitoring.Type: ApplicationFiled: January 24, 2017Publication date: December 21, 2017Applicant: The Johns Hopkins UniversityInventors: Tobias SJOBLOM, Sian JONES, D. Williams PARSONS, Laura D. WOOD, Jimmy Cheng-Ho LIN, Thomas BARBER, Diana MANDELKER, Bert VOGELSTEIN, Kenneth W. KINZLER, Victor E. VELCULESCU
-
Publication number: 20170081730Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: ApplicationFiled: November 16, 2016Publication date: March 23, 2017Applicants: The Johns Hopkins University, Duke UniversityInventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell D. Bigner, Chien-Tsun Kuan, Gregory J. Riggins
-
Patent number: 9551037Abstract: Analysis of 13,023 genes in 11 breast and 11 colorectal cancers revealed that individual tumors accumulate an average of ˜90 mutant genes but that only a subset of these contribute to the neoplastic process. Using stringent criteria to delineate this subset, we identified 189 genes (average of 11 per tumor) that were mutated at significant frequency. The vast majority of these genes were not known to be genetically altered in tumors and are predicted to affect a wide range of cellular functions, including transcription, adhesion, and invasion. These data define the genetic landscape of two human cancer types, provide new targets for diagnostic and therapeutic intervention and monitoring.Type: GrantFiled: March 25, 2014Date of Patent: January 24, 2017Assignee: The Johns Hopkins UniversityInventors: Tobias Sjoblom, Sian Jones, D. Williams Parsons, Laura D. Wood, Jimmy Cheng-Ho Lin, Thomas Barber, Diana Mandelker, Bert Vogelstein, Kenneth W. Kinzler, Victor E. Velculescu
-
Patent number: 9353418Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: GrantFiled: December 11, 2013Date of Patent: May 31, 2016Assignees: The Johns Hopkins University, Duke UniversityInventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell Bigner, Chien-Tsun Kuan, Gregory J. Riggins
-
Publication number: 20150167095Abstract: Analysis of 13,023 genes in 11 breast and 11 colorectal cancers revealed that individual tumors accumulate an average of ˜90 mutant genes but that only a subset of these contribute to the neoplastic process. Using stringent criteria to delineate this subset, we identified 189 genes (average of 11 per tumor) that were mutated at significant frequency. The vast majority of these genes were not known to be genetically altered in tumors and are predicted to affect a wide range of cellular functions, including transcription, adhesion, and invasion. These data define the genetic landscape of two human cancer types, provide new targets for diagnostic and therapeutic intervention and monitoring.Type: ApplicationFiled: March 25, 2014Publication date: June 18, 2015Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Tobias SJOBLOM, Sian JONES, D. Williams PARSONS, Laura D. WOOD, Jimmy Cheng-Ho LIN, Thomas BARBER, Diana MANDELKER, Bert VOGELSTEIN, Kenneth W. KINZLER, Victor E. VELCULESCU
-
Publication number: 20140377754Abstract: Human cancer is caused by the accumulation of mutations in oncogenes and tumor suppressor genes. To catalogue the genetic changes that occur during tumorigenesis, we isolated DNA from 11 breast and 11 colorectal tumors and determined the sequences of the genes in the Reference Sequence database in these samples. Based on analysis of exons representing 20,857 transcripts from 18,191 genes, we conclude that the genomic landscapes of breast and colorectal cancers are composed of a handful of commonly mutated gene “mountains” and a much larger number of gene “hills” that are mutated at low frequency. We describe statistical and bioinformatic tools that may help identify mutations with a role in tumorigenesis. These results have implications for understanding the nature and heterogeneity of human cancers and for using personal genomics for tumor diagnosis and therapy.Type: ApplicationFiled: August 5, 2014Publication date: December 25, 2014Inventors: Laura D. WOOD, D. Williams PARSONS, Sian JONES, Jimmy Cheng-Ho LIN, Tobias SJOBLOM, Thomas BARBER, Giovanni PARMIGIANI, Victor VELCULESCU, Kenneth W. KINZLER, Bert VOGELSTEIN
-
Publication number: 20140187764Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: ApplicationFiled: December 11, 2013Publication date: July 3, 2014Applicants: Duke University, The Johns Hopkins UniversityInventors: Bert VOGELSTEIN, Kenneth W. KINZLER, D. Williams PARSONS, Xiaosong ZHANG, Jimmy Cheng-Ho LIN, Rebecca J. LEARY, Philipp ANGENENDT, Nickolas PAPADOPOULOS, Victor VELCULESCU, Giovanni PARMIGIANI, Rachel KARCHIN, Sian JONES, Hai YAN, Darell BIGNER, Chien-Tsun KUAN, Gregory J. RIGGINS
-
Patent number: 8685660Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: GrantFiled: September 3, 2009Date of Patent: April 1, 2014Assignees: The Johns Hopkins University, Duke UniversityInventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell Bigner, Chien-Tsun Kuan, Gregory J. Riggins
-
Publication number: 20120202207Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: ApplicationFiled: March 6, 2012Publication date: August 9, 2012Applicants: DUKE UNIVERSITY, THE JOHNS HOPKINS UNIVERSITYInventors: Bert VOGELSTEIN, Kenneth W. KINZLER, D. Williams PARSONS, Xiaosong ZHANG, Jimmy Cheng-Ho LIN, Rebecca J. LEARY, Philipp ANGENENDT, Nickolas PAPADOPOULOS, Victor VELCULESCU, Giovanni PARMIGIANI, Rachel KARCHIN, Sian JONES, Hai YAN, Darell BIGNER, Chien-Tsun KUAN, Gregory J. RIGGINS
-
Publication number: 20120115735Abstract: There are currently few therapeutic options for patients with pancreatic cancers and new insights into the pathogenesis of this lethal disease are urgently needed. To this end, we performed a comprehensive analysis of the genes altered in 24 pancreatic tumors. First, we determined the sequences of 23,781 transcripts, representing 20,583 protein-encoding genes, in DNA from these tumors. Second, we searched for homozygous deletions and amplifications using microarrays querying ˜one million single nucleotide polymorphisms in each sample. Third, we analyzed the transcriptomes of the same samples using SAGE and next-generation sequencing-by-synthesis technologies. We found that pancreatic cancers contain an average of 63 genetic alterations, of which 49 are point mutations, 8 are homozygous deletions, and 6 are amplifications. Further analyses revealed a core set of 12 regulatory processes or pathways that were each genetically altered in 70% to 100% of the samples.Type: ApplicationFiled: September 3, 2009Publication date: May 10, 2012Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Sian Jones, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Scott Kern, Ralph Hruban, James R. Eshleman, Michael Goggins, Alison Klein
-
Publication number: 20110229479Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: ApplicationFiled: September 3, 2009Publication date: September 22, 2011Applicants: THE JOHNS HOPKINS UNIVERSITY, DUKE UNIVERSITYInventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell Bigner, Chien-Tsun Kuan